 | This article needs to be updated. (January 2014) |
| Company type | Public |
|---|---|
| TSX: ONC, Nasdaq: ONCY | |
| Industry | Biopharmaceutical |
| Founded | 1998 Calgary, Alberta, Canada |
| Headquarters | , |
Key people | Matt Coffey - President, and Chief Executive Officer, Chief Operating Officer; Kirk Look - Chief Financial Officer; Andres A. Gutierrez - Chief Medical Officer; Andrew de Guttadauro, President, Oncolytics Biotech (U.S.) Inc. |
| Products | REOLYSIN, a first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. |
| Website | www.oncolyticsbiotech.com |
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.[1]
- ^ "What is Reolysin? | Oncolytics Biotech Inc". Oncolytics Biotech Inc. Archived from the original on 2017-10-26. Retrieved 2017-10-25.